Cannabinoid formulations

• US 10,052,303 B2
• Filed: 08/03/2015
• Issued: 08/21/2018
• Est. Priority Date: 07/11/2011
• Status: Active Grant

• Current Assignee: Teewinot Technologies Limited (Teewinot Life Sciences Corp.)
• Original Assignee: Teewinot Technologies Limited (Teewinot Life Sciences Corp.)
• Inventors: Winnicki, Robert
• Primary Examiner(s): Shomer, Isaac
• Application Number:
  US14/816,959
• Publication Number:
  US 20160030387A1
• Time in Patent Office: 1,114 Days
• Field of Search: None
• CPC Class Codes: A23L 33/105 Plant extracts, their artificial duplicates or their derivatives
• CPC Class Codes: A23V 2002/00 Food compositions, function of food ingredients or processes for food or foodstuffs
• CPC Class Codes: A61K 31/05 Phenols cannabinoids A61K31/658
• CPC Class Codes: A61K 31/352 condensed with carbocyclic rings, e.g. methantheline cannabinoids A61K31/658
• CPC Class Codes: A61K 36/185 Magnoliopsida (dicotyledons)
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61K 47/10 Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
• CPC Class Codes: A61K 47/24 containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
• CPC Class Codes: A61K 47/36 Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
• CPC Class Codes: A61K 9/107 Emulsions ; Emulsion preconcentrates; Micelles composition of emulsions A61K47/00
• CPC Class Codes: A61K 9/1075 Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers A61K9/0026 takes precedence
• CPC Class Codes: A61K 9/127 Liposomes

Abstract

The present invention provides stable, fast-acting liposomal and micelle formulations of cannabinoids that are suitable for pharmaceutical and nutraceutical applications.

Claims

1. A formulation comprising a liquid aqueous unilamellar liposome suspension of one or more cannabinoids or cannabinoid analogues, and a stabilizer selected from the group consisting of guar gum, xanthan gum cellulose hyaluronic acid, polyvinyl pyrrolidone (PVP), alginate, chondritin sulfate, poly gamma glutamic acid, gelatin, chitosan, corn starch and flour, wherein the concentration of one or more cannabinoids or cannabinoid analogues in the liposome suspension is from about 150 mg/mL to about 300 mg/mL, and wherein the suspension is thermostable at temperatures greater than 50°

C.,

wherein the stabilizer is present in a concentration from about 0.25% to about 2% (w/v) or at about 4% (w/v).

2. The formulation of claim 1, wherein the one or more cannabinoids or cannabinoid analogues are one or more of a natural compound, a synthetic compound, a semi-synthetic compound, or mixtures thereof.

3. The formulation of claim 2, wherein the one or more cannabinoids or cannabinoid analogues are one or more of cannabinol, cannabidiol, Δ

9-tetrahydrocannabinol, Δ

8-tetrahydrocannabinol, 11-hydroxy-tetrahydrocannabinol, 11-hydroxy-Δ

9-tetrahydrocannabinol, levonantradol, Δ

11-tetrahydrocannabinol, tetrahydrocannabivarin, dronabinol, amandamide, nabilone, a combination thereof, a natural or synthetic analogue thereof, or a natural or synthetic molecule with a basic cannabinoid structure.

4. The formulation of claim 1, wherein the formulation is a composition for parenteral injection, a dietary composition for oral delivery or a composition for topical administration.

5. The formulation of claim 4, wherein the formulation is for topical administration wherein the formulation further comprises an agent that favors penetration into the skin.

6. The formulation of claim 4, wherein the dietary composition is a soup, or a liquid dairy product.

7. The formulation of claim 1, wherein the formulation is a liposomal suspension, and wherein the liposomes have an average diameter from about 100 nm to about 400 nm.

8. A method of alleviating pain or reducing undesirable side effects associated with radiation therapy or chemotherapy in a subject having a compromised immune system, a cancer, a pulmonary disease or a condition that causes violent tremors comprising administering to the subject the formulation of claim 1.